SlideShare a Scribd company logo
1 of 18
Anticancer
Alkylating agents
Dr. S. Parasuraman
Faculty of Pharmacy, AIMST.
Alkylating agents
Nitrogen mustards

Ethylenimine
Alkyl sulfonate
Nitrosoureas
Triazine
Methylhyderazine

Mechlorethamine
Cyclophosphamide
Ifosfamide
Chlorambucil
Melphalan
Thio-TEPA
Busulfan
Carmustine
Lomustine
Dacarbazine
Temozolomide
Procarbazine
Alkylating agents
• Alkylating agents produce highly reactive carbonium ion
intermediates or related transition complex which
transfer alkyl group to cellular macromolecules by
covalent bonds.

• Alkylating agents cross link with carboxyl, hydroxyl,
amino,

sulfhydryl

and

phosphate

groups

of

biomacromolecules results abnormal base paring/
scission of DNA Stand.
Alkylating agents
MOA & SAR:

The chemotherapeutic
and cytotoxic effects
are directly related to
the alkylation of DNA.
The 7th nitrogen atom
of guanine is suitable
for
formation
of
covalent bond with
bifunctional alkylating
agent.
Pharmacological actions
• Cytotoxic actions:
– Interfere with DNA integrity and functions to induce cell

death in rapidly proliferating tissues.
– Lethality of DNA alkylation depends on the recognition of
the adduct, the creation of DNA stand breaks by repair

enzymes.
– In nondividing cells, DNA damage activation depends on the
presence of p53 gene. Malignant cells with mutant/ absent

p53 gene fail to suspend cell-cycle progression (don’t cause
apoptosis) and exhibit resistance to alkylating agents.
Toxicities of alkylating agents
• Bone marrow toxicity
– Causes dose-dependent toxicity to bone marrow elements
– Myelosuppression
– Suppression of cellular and humoral immunity

• Mucosal toxicity
– Highly toxic to mucosal cells and intestinal mucosa

• Neurotoxicity
– Nausea, vomiting (after I.V administration)
– Ifosfamide is the most neurotoxic agent in this class (alter
mental status, coma, generalized seizures and cerebellar ataxia)

• Other: Leukemogensis, male and female reproductive
system toxicity.
• Mechlorethamine
–
–
–
–
–

First nitrogen mustard; most reactive
Slow I.V. injection may cause sloughing
Used for Hodgkin and non-Hodgkin lymphomas
Largely replaced by cyclophosphamide and melphalan.
Dose: 0.1 mg/kg i.v. daily X 4 days (courses may be
repeated at suitable intervals)
– It is also used topically for treatment of cutaneous T-cell
lymphoma
– Toxicity: Block reproductive functions, produce menstrual
irregularities or premature ovarian failure in women and
oligospermia in men. First trimester of pregnancy and later
stage of pregnancy it should not be used.
• Cyclophosphosphamide
– Inactive as such
– Transformed to active metabolites in liver:
(aldophosphamide, phosphoramide mustard)
– Chloramphenicol retards the metabolism of
cyclophosphamide.
– It is well absorbed orally, activated by CYP2B.
– Cyclophosphamide is potent immunosuppressive agent, it
has been used to prevent organ rejection after
transplantation.
– Dose: 2-3 mg/kg/ day oral; 10-15 mg/kg i.v.
• Ifosfamide
– Analog of cyclophosphamide has a longer dose-dependent
t1/2 and it also activated by hydroxylation in the liver.
– Used in bronchogenic, breast, testicular, bladder, head and
neck carcinomas, oeseogenic sarcoma and some lymphomas.
– Approved for germ cell testicular cancer
– Produce dose limiting toxicity – haemorrhagic cystitis. Sever
urinary tract and CNS toxicity
– Toxicity can be reduced by administering mesna (-SH
compound). mesna inactivates the vasicotoxic metabolites of
ifosfamide and cyclophosphamide.
– Ifosfamide causes less alopecia and is less emetogenic than
cyclophosphamide.
– Dose: 0.1 g inj.
• Chlorambucil
– Slow acting alkylating agent
– Active against lymphoid, myeloid tissue cancers
– It is the drug of choice for the long-term maintenance
therapy for chronic lymphatic leukaemia, non-Hodgkin
lymphoma and few solid tumours.
– It has immunosuppressant property
– Dose: 4-10 mg daily for 3-6 weeks, then 2 mg/kg daily for
maintenance
• Melphalan
– The pharmacological and cytotoxic properties of
melphalan is similar to mechlorethamine. The drug is not a
vesicant
– Effective in multiple myeloma and advanced ovarian
cancer
– Toxicity: Bone marrow toxicity
– Dose: 10 mg daily for 7 days or 6 mg/ day for 2-3 weeks-----------4 weeks gap--------- 2 to 4 mg/day for maintenance
orally.
• Thio-TEPA
–
–
–
–

It is an ethylenimine
Highly toxic
Used in ovarian and bladder cancer
Dose: 0.3-0.4 mg/kg i.v. at 1-4 weeks intervels
• Busulfan
– Highly specific for myeloid elements and granulocyte
– Toxicity: hyperuricaemia is common; pulmonary fibrosis
and skin pigmentation are specific adverse effects.
– Drug of choice for chronic myeloid leukaemia
– Dose: 2-6 mg/ day, orally
• Nitrosoureas
– It is lipid soluble alkylating agents with a wide range of
antitumour activity.
– Cross BBM
– Effective in meningeal leukaemias and brain cancer
– Toxicity: Nausea, vomiting are common; CNS toxicity, bone
marrow depression (delayed effect; will take 6 weeks to
develop), visceral fibrosis and renal damage can occur
– Dose: 100-130 mg/m2 BSA single oral dose every 6 weeks.
• Dacarbazine (DTIC)
– After activation in liver, the active metabolite methylate
the DNA and interfere with its function.
– Used for malignant melanoma, Hodgkin’s disease
– Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy
and myelosuppression
– Dose: 3.5 mg/kg/day i.v. for 10 days, repeated after 4
weeks
• Temozolamide
– Orally active triazine methylating agent is the drug of
choice for glioma and other malignant brain tumour.
– Also used for melanoma
– Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy
and myelosuppression
– Dose: 100- 200 mg/day
• Procarbazine
– It is not classical alkylating agent, but has similar
properties.
– After metabolizing, procarbazine methylates and
depolymerizes DNA and causing chromosomal damage
and inhibit nucleic acid synthesis.
– Procarbazine is component of MOPP regimen for Hodgkin’s
and related lymphomas and alternative drug for brain
tumours.
– It is a week MAO inhibitor, produce sedation and other
CNS effects.
– Interact with food, drugs and alcohol. With alcohol,
procarbazine causes hot flushing and disulfiram-like
reaction.
– Toxicity: Vomiting, leucopenia, thrombocytopenia
– Dose: 100 mg/m2/ dayfor 14 days in 28 days cycle.
Thank you

More Related Content

What's hot

ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.Dr. Ravi Sankar
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extraNilesh Kucha
 
medicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agentsmedicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agentsGanesh Mote
 
Class anticancer drugs
Class anticancer drugsClass anticancer drugs
Class anticancer drugsRaghu Prasada
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsDHARMENDRA BARIA
 
Anticancer drugs 1 introduction and classification
Anticancer drugs 1 introduction and classificationAnticancer drugs 1 introduction and classification
Anticancer drugs 1 introduction and classificationSubramani Parasuraman
 
Antineoplastic agents
Antineoplastic agentsAntineoplastic agents
Antineoplastic agentsRobin Gulati
 
Antineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugsAntineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugskencha swathi
 
Anticancer drugs: Classification , general toxicity and Alkylating agents.
Anticancer drugs: Classification , general toxicity and Alkylating agents.Anticancer drugs: Classification , general toxicity and Alkylating agents.
Anticancer drugs: Classification , general toxicity and Alkylating agents.Ameena Kadar
 
Alkylating agents and antimetabolites
Alkylating agents and antimetabolitesAlkylating agents and antimetabolites
Alkylating agents and antimetabolitesGedion Yilma
 
Antineoplastic agents(ravisankar)
Antineoplastic agents(ravisankar)Antineoplastic agents(ravisankar)
Antineoplastic agents(ravisankar)Dr. Ravi Sankar
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapyGamitKinjal
 

What's hot (20)

10.ANTICANCER DRUGS
10.ANTICANCER DRUGS10.ANTICANCER DRUGS
10.ANTICANCER DRUGS
 
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extra
 
medicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agentsmedicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agents
 
Class anticancer drugs
Class anticancer drugsClass anticancer drugs
Class anticancer drugs
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agents
 
Anticancer drugs 1 introduction and classification
Anticancer drugs 1 introduction and classificationAnticancer drugs 1 introduction and classification
Anticancer drugs 1 introduction and classification
 
Antineoplastic agents
Antineoplastic agentsAntineoplastic agents
Antineoplastic agents
 
Anticancer drugs - drdhriti
Anticancer drugs - drdhritiAnticancer drugs - drdhriti
Anticancer drugs - drdhriti
 
Antimetabolites
AntimetabolitesAntimetabolites
Antimetabolites
 
Antineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugsAntineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugs
 
Anticancer drugs: Classification , general toxicity and Alkylating agents.
Anticancer drugs: Classification , general toxicity and Alkylating agents.Anticancer drugs: Classification , general toxicity and Alkylating agents.
Anticancer drugs: Classification , general toxicity and Alkylating agents.
 
Alkylating agents and antimetabolites
Alkylating agents and antimetabolitesAlkylating agents and antimetabolites
Alkylating agents and antimetabolites
 
Antineoplastic agents(ravisankar)
Antineoplastic agents(ravisankar)Antineoplastic agents(ravisankar)
Antineoplastic agents(ravisankar)
 
Vinca alkaloids
Vinca alkaloidsVinca alkaloids
Vinca alkaloids
 
Anti Cancer Drugs
Anti Cancer DrugsAnti Cancer Drugs
Anti Cancer Drugs
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
 
ANTI METABOLITES.pptx
ANTI METABOLITES.pptxANTI METABOLITES.pptx
ANTI METABOLITES.pptx
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapy
 
Quinolones
QuinolonesQuinolones
Quinolones
 

Similar to Anticancer drugs 2 alkylating agents

2. alkylating & anti-metabolite drugs
2. alkylating  &  anti-metabolite drugs2. alkylating  &  anti-metabolite drugs
2. alkylating & anti-metabolite drugsHarshikaPatel6
 
ALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxDevakiKondaveeti2
 
ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfrazee khwaja
 
Anticancer drugs1
Anticancer drugs1Anticancer drugs1
Anticancer drugs1sarekat7
 
Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry NarminHamaaminHussen
 
Chemotherapeutic agents
Chemotherapeutic agents Chemotherapeutic agents
Chemotherapeutic agents prachiupadhyay8
 
Classification of anti cancer drugs
Classification of anti cancer drugs Classification of anti cancer drugs
Classification of anti cancer drugs pgclubrcc
 
Chemotherapeutic agents in ENT
Chemotherapeutic agents in ENTChemotherapeutic agents in ENT
Chemotherapeutic agents in ENTAVINAV GUPTA
 
Chemotherapy in Breast Cancer
Chemotherapy in Breast CancerChemotherapy in Breast Cancer
Chemotherapy in Breast CancerDr. Shaurya Mehra
 
Chemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologyChemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologySravanthi Nuthalapati
 
Neoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic AgentsNeoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic Agentspankaj patel
 
Anticancer compounds.ppt
Anticancer compounds.pptAnticancer compounds.ppt
Anticancer compounds.pptPravinKhatale2
 
CHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTCHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTRazal M
 
Cytotoxic Drug.pptx
Cytotoxic Drug.pptxCytotoxic Drug.pptx
Cytotoxic Drug.pptxTabel el
 

Similar to Anticancer drugs 2 alkylating agents (20)

2. alkylating & anti-metabolite drugs
2. alkylating  &  anti-metabolite drugs2. alkylating  &  anti-metabolite drugs
2. alkylating & anti-metabolite drugs
 
ALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptx
 
ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdf
 
Anticancer drugs1
Anticancer drugs1Anticancer drugs1
Anticancer drugs1
 
Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry
 
Chemotherapeutic agents
Chemotherapeutic agents Chemotherapeutic agents
Chemotherapeutic agents
 
Classification of anti cancer drugs
Classification of anti cancer drugs Classification of anti cancer drugs
Classification of anti cancer drugs
 
Chemotherapeutic agents in ENT
Chemotherapeutic agents in ENTChemotherapeutic agents in ENT
Chemotherapeutic agents in ENT
 
Antituberculosis drugs
Antituberculosis drugsAntituberculosis drugs
Antituberculosis drugs
 
Chemotherapy in Breast Cancer
Chemotherapy in Breast CancerChemotherapy in Breast Cancer
Chemotherapy in Breast Cancer
 
Anti tuberculin drugs [autosaved]
Anti tuberculin drugs [autosaved]Anti tuberculin drugs [autosaved]
Anti tuberculin drugs [autosaved]
 
Anticancer drugs
Anticancer drugsAnticancer drugs
Anticancer drugs
 
Chemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologyChemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncology
 
Neoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic AgentsNeoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic Agents
 
Dapsone, colchicine
Dapsone, colchicineDapsone, colchicine
Dapsone, colchicine
 
Antituberculosis drugs converted
Antituberculosis drugs convertedAntituberculosis drugs converted
Antituberculosis drugs converted
 
Anticancer compounds.ppt
Anticancer compounds.pptAnticancer compounds.ppt
Anticancer compounds.ppt
 
CHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTCHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENT
 
chemotheraphy in ent.pdf
chemotheraphy in ent.pdfchemotheraphy in ent.pdf
chemotheraphy in ent.pdf
 
Cytotoxic Drug.pptx
Cytotoxic Drug.pptxCytotoxic Drug.pptx
Cytotoxic Drug.pptx
 

More from Subramani Parasuraman

Role of preclinical studies in drug discovery
Role of preclinical studies in drug discoveryRole of preclinical studies in drug discovery
Role of preclinical studies in drug discoverySubramani Parasuraman
 
Tolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptxTolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptxSubramani Parasuraman
 
Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Subramani Parasuraman
 
Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Subramani Parasuraman
 
Sustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptxSustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptxSubramani Parasuraman
 
Role of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptxRole of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptxSubramani Parasuraman
 
Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptxSubramani Parasuraman
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxSubramani Parasuraman
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disordersSubramani Parasuraman
 

More from Subramani Parasuraman (20)

Role of preclinical studies in drug discovery
Role of preclinical studies in drug discoveryRole of preclinical studies in drug discovery
Role of preclinical studies in drug discovery
 
Tolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptxTolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptx
 
Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)
 
Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)
 
Sustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptxSustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptx
 
Role of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptxRole of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptx
 
Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptx
 
Nicotine and Tobacco
Nicotine and TobaccoNicotine and Tobacco
Nicotine and Tobacco
 
Statistical software.pptx
Statistical software.pptxStatistical software.pptx
Statistical software.pptx
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptx
 
Drugs Used in Renal Alteration
Drugs Used in Renal AlterationDrugs Used in Renal Alteration
Drugs Used in Renal Alteration
 
Drugs Used in Endocrine Alteration
Drugs Used in Endocrine AlterationDrugs Used in Endocrine Alteration
Drugs Used in Endocrine Alteration
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Pancreatic Hormones
Pancreatic HormonesPancreatic Hormones
Pancreatic Hormones
 
Terrestrial laboratory animals
Terrestrial laboratory animalsTerrestrial laboratory animals
Terrestrial laboratory animals
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disorders
 
Laboratory animals
Laboratory animalsLaboratory animals
Laboratory animals
 
Immunomodulators-1.pptx
Immunomodulators-1.pptxImmunomodulators-1.pptx
Immunomodulators-1.pptx
 
Immunomodulators - 3.pptx
Immunomodulators - 3.pptxImmunomodulators - 3.pptx
Immunomodulators - 3.pptx
 
Immunomodulators - 2.pptx
Immunomodulators - 2.pptxImmunomodulators - 2.pptx
Immunomodulators - 2.pptx
 

Recently uploaded

Andreas Schleicher presents at the launch of What does child empowerment mean...
Andreas Schleicher presents at the launch of What does child empowerment mean...Andreas Schleicher presents at the launch of What does child empowerment mean...
Andreas Schleicher presents at the launch of What does child empowerment mean...EduSkills OECD
 
Improved Approval Flow in Odoo 17 Studio App
Improved Approval Flow in Odoo 17 Studio AppImproved Approval Flow in Odoo 17 Studio App
Improved Approval Flow in Odoo 17 Studio AppCeline George
 
Implanted Devices - VP Shunts: EMGuidewire's Radiology Reading Room
Implanted Devices - VP Shunts: EMGuidewire's Radiology Reading RoomImplanted Devices - VP Shunts: EMGuidewire's Radiology Reading Room
Implanted Devices - VP Shunts: EMGuidewire's Radiology Reading RoomSean M. Fox
 
Features of Video Calls in the Discuss Module in Odoo 17
Features of Video Calls in the Discuss Module in Odoo 17Features of Video Calls in the Discuss Module in Odoo 17
Features of Video Calls in the Discuss Module in Odoo 17Celine George
 
MOOD STABLIZERS DRUGS.pptx
MOOD     STABLIZERS           DRUGS.pptxMOOD     STABLIZERS           DRUGS.pptx
MOOD STABLIZERS DRUGS.pptxPoojaSen20
 
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45MysoreMuleSoftMeetup
 
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...Nguyen Thanh Tu Collection
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxheathfieldcps1
 
Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).Mohamed Rizk Khodair
 
The Liver & Gallbladder (Anatomy & Physiology).pptx
The Liver &  Gallbladder (Anatomy & Physiology).pptxThe Liver &  Gallbladder (Anatomy & Physiology).pptx
The Liver & Gallbladder (Anatomy & Physiology).pptxVishal Singh
 
Spring gala 2024 photo slideshow - Celebrating School-Community Partnerships
Spring gala 2024 photo slideshow - Celebrating School-Community PartnershipsSpring gala 2024 photo slideshow - Celebrating School-Community Partnerships
Spring gala 2024 photo slideshow - Celebrating School-Community Partnershipsexpandedwebsite
 
How to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 InventoryHow to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 InventoryCeline George
 
UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024Borja Sotomayor
 
Benefits and Challenges of OER by Shweta Babel.pptx
Benefits and Challenges of OER by Shweta Babel.pptxBenefits and Challenges of OER by Shweta Babel.pptx
Benefits and Challenges of OER by Shweta Babel.pptxsbabel
 
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjjStl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjjMohammed Sikander
 
Đề tieng anh thpt 2024 danh cho cac ban hoc sinh
Đề tieng anh thpt 2024 danh cho cac ban hoc sinhĐề tieng anh thpt 2024 danh cho cac ban hoc sinh
Đề tieng anh thpt 2024 danh cho cac ban hoc sinhleson0603
 
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...Nguyen Thanh Tu Collection
 

Recently uploaded (20)

Andreas Schleicher presents at the launch of What does child empowerment mean...
Andreas Schleicher presents at the launch of What does child empowerment mean...Andreas Schleicher presents at the launch of What does child empowerment mean...
Andreas Schleicher presents at the launch of What does child empowerment mean...
 
Improved Approval Flow in Odoo 17 Studio App
Improved Approval Flow in Odoo 17 Studio AppImproved Approval Flow in Odoo 17 Studio App
Improved Approval Flow in Odoo 17 Studio App
 
Implanted Devices - VP Shunts: EMGuidewire's Radiology Reading Room
Implanted Devices - VP Shunts: EMGuidewire's Radiology Reading RoomImplanted Devices - VP Shunts: EMGuidewire's Radiology Reading Room
Implanted Devices - VP Shunts: EMGuidewire's Radiology Reading Room
 
Features of Video Calls in the Discuss Module in Odoo 17
Features of Video Calls in the Discuss Module in Odoo 17Features of Video Calls in the Discuss Module in Odoo 17
Features of Video Calls in the Discuss Module in Odoo 17
 
MOOD STABLIZERS DRUGS.pptx
MOOD     STABLIZERS           DRUGS.pptxMOOD     STABLIZERS           DRUGS.pptx
MOOD STABLIZERS DRUGS.pptx
 
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
Exploring Gemini AI and Integration with MuleSoft | MuleSoft Mysore Meetup #45
 
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
TỔNG HỢP HƠN 100 ĐỀ THI THỬ TỐT NGHIỆP THPT VẬT LÝ 2024 - TỪ CÁC TRƯỜNG, TRƯ...
 
IPL Online Quiz by Pragya; Question Set.
IPL Online Quiz by Pragya; Question Set.IPL Online Quiz by Pragya; Question Set.
IPL Online Quiz by Pragya; Question Set.
 
The basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptxThe basics of sentences session 4pptx.pptx
The basics of sentences session 4pptx.pptx
 
Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).Dementia (Alzheimer & vasular dementia).
Dementia (Alzheimer & vasular dementia).
 
The Liver & Gallbladder (Anatomy & Physiology).pptx
The Liver &  Gallbladder (Anatomy & Physiology).pptxThe Liver &  Gallbladder (Anatomy & Physiology).pptx
The Liver & Gallbladder (Anatomy & Physiology).pptx
 
Spring gala 2024 photo slideshow - Celebrating School-Community Partnerships
Spring gala 2024 photo slideshow - Celebrating School-Community PartnershipsSpring gala 2024 photo slideshow - Celebrating School-Community Partnerships
Spring gala 2024 photo slideshow - Celebrating School-Community Partnerships
 
How to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 InventoryHow to Manage Closest Location in Odoo 17 Inventory
How to Manage Closest Location in Odoo 17 Inventory
 
UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024UChicago CMSC 23320 - The Best Commit Messages of 2024
UChicago CMSC 23320 - The Best Commit Messages of 2024
 
Word Stress rules esl .pptx
Word Stress rules esl               .pptxWord Stress rules esl               .pptx
Word Stress rules esl .pptx
 
“O BEIJO” EM ARTE .
“O BEIJO” EM ARTE                       .“O BEIJO” EM ARTE                       .
“O BEIJO” EM ARTE .
 
Benefits and Challenges of OER by Shweta Babel.pptx
Benefits and Challenges of OER by Shweta Babel.pptxBenefits and Challenges of OER by Shweta Babel.pptx
Benefits and Challenges of OER by Shweta Babel.pptx
 
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjjStl Algorithms in C++ jjjjjjjjjjjjjjjjjj
Stl Algorithms in C++ jjjjjjjjjjjjjjjjjj
 
Đề tieng anh thpt 2024 danh cho cac ban hoc sinh
Đề tieng anh thpt 2024 danh cho cac ban hoc sinhĐề tieng anh thpt 2024 danh cho cac ban hoc sinh
Đề tieng anh thpt 2024 danh cho cac ban hoc sinh
 
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
ĐỀ THAM KHẢO KÌ THI TUYỂN SINH VÀO LỚP 10 MÔN TIẾNG ANH FORM 50 CÂU TRẮC NGHI...
 

Anticancer drugs 2 alkylating agents

  • 1. Anticancer Alkylating agents Dr. S. Parasuraman Faculty of Pharmacy, AIMST.
  • 2. Alkylating agents Nitrogen mustards Ethylenimine Alkyl sulfonate Nitrosoureas Triazine Methylhyderazine Mechlorethamine Cyclophosphamide Ifosfamide Chlorambucil Melphalan Thio-TEPA Busulfan Carmustine Lomustine Dacarbazine Temozolomide Procarbazine
  • 3. Alkylating agents • Alkylating agents produce highly reactive carbonium ion intermediates or related transition complex which transfer alkyl group to cellular macromolecules by covalent bonds. • Alkylating agents cross link with carboxyl, hydroxyl, amino, sulfhydryl and phosphate groups of biomacromolecules results abnormal base paring/ scission of DNA Stand.
  • 4. Alkylating agents MOA & SAR: The chemotherapeutic and cytotoxic effects are directly related to the alkylation of DNA. The 7th nitrogen atom of guanine is suitable for formation of covalent bond with bifunctional alkylating agent.
  • 5. Pharmacological actions • Cytotoxic actions: – Interfere with DNA integrity and functions to induce cell death in rapidly proliferating tissues. – Lethality of DNA alkylation depends on the recognition of the adduct, the creation of DNA stand breaks by repair enzymes. – In nondividing cells, DNA damage activation depends on the presence of p53 gene. Malignant cells with mutant/ absent p53 gene fail to suspend cell-cycle progression (don’t cause apoptosis) and exhibit resistance to alkylating agents.
  • 6. Toxicities of alkylating agents • Bone marrow toxicity – Causes dose-dependent toxicity to bone marrow elements – Myelosuppression – Suppression of cellular and humoral immunity • Mucosal toxicity – Highly toxic to mucosal cells and intestinal mucosa • Neurotoxicity – Nausea, vomiting (after I.V administration) – Ifosfamide is the most neurotoxic agent in this class (alter mental status, coma, generalized seizures and cerebellar ataxia) • Other: Leukemogensis, male and female reproductive system toxicity.
  • 7. • Mechlorethamine – – – – – First nitrogen mustard; most reactive Slow I.V. injection may cause sloughing Used for Hodgkin and non-Hodgkin lymphomas Largely replaced by cyclophosphamide and melphalan. Dose: 0.1 mg/kg i.v. daily X 4 days (courses may be repeated at suitable intervals) – It is also used topically for treatment of cutaneous T-cell lymphoma – Toxicity: Block reproductive functions, produce menstrual irregularities or premature ovarian failure in women and oligospermia in men. First trimester of pregnancy and later stage of pregnancy it should not be used.
  • 8. • Cyclophosphosphamide – Inactive as such – Transformed to active metabolites in liver: (aldophosphamide, phosphoramide mustard) – Chloramphenicol retards the metabolism of cyclophosphamide. – It is well absorbed orally, activated by CYP2B. – Cyclophosphamide is potent immunosuppressive agent, it has been used to prevent organ rejection after transplantation. – Dose: 2-3 mg/kg/ day oral; 10-15 mg/kg i.v.
  • 9. • Ifosfamide – Analog of cyclophosphamide has a longer dose-dependent t1/2 and it also activated by hydroxylation in the liver. – Used in bronchogenic, breast, testicular, bladder, head and neck carcinomas, oeseogenic sarcoma and some lymphomas. – Approved for germ cell testicular cancer – Produce dose limiting toxicity – haemorrhagic cystitis. Sever urinary tract and CNS toxicity – Toxicity can be reduced by administering mesna (-SH compound). mesna inactivates the vasicotoxic metabolites of ifosfamide and cyclophosphamide. – Ifosfamide causes less alopecia and is less emetogenic than cyclophosphamide. – Dose: 0.1 g inj.
  • 10. • Chlorambucil – Slow acting alkylating agent – Active against lymphoid, myeloid tissue cancers – It is the drug of choice for the long-term maintenance therapy for chronic lymphatic leukaemia, non-Hodgkin lymphoma and few solid tumours. – It has immunosuppressant property – Dose: 4-10 mg daily for 3-6 weeks, then 2 mg/kg daily for maintenance
  • 11. • Melphalan – The pharmacological and cytotoxic properties of melphalan is similar to mechlorethamine. The drug is not a vesicant – Effective in multiple myeloma and advanced ovarian cancer – Toxicity: Bone marrow toxicity – Dose: 10 mg daily for 7 days or 6 mg/ day for 2-3 weeks-----------4 weeks gap--------- 2 to 4 mg/day for maintenance orally.
  • 12. • Thio-TEPA – – – – It is an ethylenimine Highly toxic Used in ovarian and bladder cancer Dose: 0.3-0.4 mg/kg i.v. at 1-4 weeks intervels
  • 13. • Busulfan – Highly specific for myeloid elements and granulocyte – Toxicity: hyperuricaemia is common; pulmonary fibrosis and skin pigmentation are specific adverse effects. – Drug of choice for chronic myeloid leukaemia – Dose: 2-6 mg/ day, orally
  • 14. • Nitrosoureas – It is lipid soluble alkylating agents with a wide range of antitumour activity. – Cross BBM – Effective in meningeal leukaemias and brain cancer – Toxicity: Nausea, vomiting are common; CNS toxicity, bone marrow depression (delayed effect; will take 6 weeks to develop), visceral fibrosis and renal damage can occur – Dose: 100-130 mg/m2 BSA single oral dose every 6 weeks.
  • 15. • Dacarbazine (DTIC) – After activation in liver, the active metabolite methylate the DNA and interfere with its function. – Used for malignant melanoma, Hodgkin’s disease – Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy and myelosuppression – Dose: 3.5 mg/kg/day i.v. for 10 days, repeated after 4 weeks
  • 16. • Temozolamide – Orally active triazine methylating agent is the drug of choice for glioma and other malignant brain tumour. – Also used for melanoma – Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy and myelosuppression – Dose: 100- 200 mg/day
  • 17. • Procarbazine – It is not classical alkylating agent, but has similar properties. – After metabolizing, procarbazine methylates and depolymerizes DNA and causing chromosomal damage and inhibit nucleic acid synthesis. – Procarbazine is component of MOPP regimen for Hodgkin’s and related lymphomas and alternative drug for brain tumours. – It is a week MAO inhibitor, produce sedation and other CNS effects. – Interact with food, drugs and alcohol. With alcohol, procarbazine causes hot flushing and disulfiram-like reaction. – Toxicity: Vomiting, leucopenia, thrombocytopenia – Dose: 100 mg/m2/ dayfor 14 days in 28 days cycle.

Editor's Notes

  1. MOPP is a combination chemotherapy regimen used to treat Hodgkin's disease. The acronym is derived from the component drugs of the regimen:Mustargen (also known as mechlorethamine, mustine, nitrogen mustard, or MSD)Oncovin (also known as Vincristine or VCR)Procarbazine (also known as Matulane or Natulan) Prednisone (also known as Deltasone or Orasone)